Abstract:Embryonic stem cell pathways such as hedgehog and Wnt pathways are central to the tumorigenic properties of cancer stem cells (CSC). Since CSCs are characterized by their ability to self-renew, form differentiated progeny, and develop resistance to anticancer therapies, targeting the Wnt and hedgehog signaling pathways has been an important strategy for cancer treatment. Although molecules targeting either Wnt or hedgehog are common, to the best of our knowledge, those targeting both pathways have not been documented. Here we report a small molecule (compound 1) that inhibits both Wnt (IC50 = 0.5 nM) and hedgehog (IC50 = 71 nM) pathways based on reporter gene assays. We further identified that the molecular target of 1 for Wnt pathway inhibition was porcupine (a member of the membrane-bound O-acyltransferase family of proteins), a post-translational modification node in Wnt signaling; while the target of 1 mitigating hedgehog pathway was Smoothened, a key G protein coupled receptor (GPCR) mediating hedgehog signal transduction. Preliminary analysis of structure-activity-relationship identified key functional elements for hedgehog/Wnt inhibition. In in vivo studies, compound 1 demonstrated good oral exposure and bioavailability while eliciting no overt toxicity in mice. An important consideration in cancer treatment is the potential therapeutic escape through compensatory activation of an interconnected pathway when only one signaling pathway is inhibited. Toward this end, compound 1 may not only lead to the development of new therapeutics for Wnt and hedgehog related cancers, but may also help to develop potential cancer treatment which needs to target Wnt and hedgehog signaling simultaneously.

The Development of Highly Potent Inhibitors for Porcupine.

Exploration of the Linkage Elements of Porcupine Antagonists Led to Potent Wnt Signaling Pathway Inhibitors.

Design, Synthesis, and Evaluation of Novel Porcupine Inhibitors Featuring a Fused 3-Ring System Based on the 'reversed' Amide Scaffold.

Design, Synthesis, and Evaluation of Potent Wnt Signaling Inhibitors Featuring a Fused 3-Ring System.

Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974

Porcupine-mediated lipid-modification regulates the activity and distribution of Wnt proteins in the chick neural tube

Discovery and Characterization of a Potent Wnt and Hedgehog Signaling Pathways Dual Inhibitor.

Novel PORCN inhibitor WHN-88 targets Wnt/β-catenin pathway and prevents the growth of Wnt-driven cancers

Inhibiting WNT secretion reduces high bone mass caused by Sost loss-of-function or gain-of-function mutations in Lrp5

Small-Molecule Inhibitors Targeting the Canonical WNT Signaling Pathway for the Treatment of Cancer

Design,synthesis and activity study of aminopeptidase N targeted N-substituted-2,5-dioxopyrrolidin peptidomimetics

Design of a Potent, Selective, and Brain-Penetrant Inhibitor of Wnt-Deactivating Enzyme Notum by Optimization of a Crystallographic Fragment Hit

Inhibition of CBP/β-catenin and porcupine attenuates Wnt signaling and induces apoptosis in head and neck carcinoma cells

Structure-activity relationship studies of small-molecule inhibitors of Wnt response.

A highly enantioselective intramolecular 1,3-dipolar cycloaddition yields novel pseudo-natural product inhibitors of the Hedgehog signaling pathway

Model‐based dose selection to inform translational clinical oncology development of WNT974, a first‐in‐class Porcupine inhibitor

Discovery and Characterization of a Small Molecule Inhibitor of the PDZ Domain of Dishevelled

Development of Potent and Selective Degraders of PI5P4Kγ.

Computational and Structure-Based Development of High Potent Cell-Active Covalent Inhibitor Targeting the Peptidyl-Prolyl Isomerase NIMA-Interacting-1 (Pin1)

Novel Cyclic-Imide Peptidomimetics As Aminopeptidase N Inhibitors. Structure-Based Design, Chemistry and Activity Evaluation. Ii

Small-molecule inhibition of Wnt signaling through activation of casein kinase 1α